Paul W. Hoelscher - 06 Apr 2022 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP, CFO
Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Apr 2022
Net transactions value
-$29,197,397
Form type
4
Filing time
08 Apr 2022, 16:09:49 UTC
Previous filing
25 Mar 2022
Next filing
22 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $483,189 +30,275 +2886% $15.96* 31,324 06 Apr 2022 Direct
transaction HZNP Ordinary Shares Options Exercise $4,097,228 +185,060 +591% $22.14* 216,384 06 Apr 2022 Direct
transaction HZNP Ordinary Shares Sale $23,688,788 -215,335 -100% $110.01 1,049 06 Apr 2022 Direct F1, F2
transaction HZNP Ordinary Shares Sale $10,089,026 -91,710 -58% $110.01 66,673 06 Apr 2022 By LLC F3, F4, F5
holding HZNP Ordinary Shares 72,789 06 Apr 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -30,275 -100% $0.000000* 0 06 Apr 2022 Ordinary Shares 30,275 $15.96 Direct F6
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -185,060 -68% $0.000000 86,424 06 Apr 2022 Ordinary Shares 185,060 $22.14 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.22 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2021.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 These securities are held of record by Riviera Equity LLC. The Reporting Person and his spouse share voting power over the securities held by Riviera Equity LLC.
F6 The option is fully vested and exercisable.